Abstract
Background
Obesity is known to cause metabolic disturbances including insulin resistance, dyslipidemia and alters bone mineralization. The effects of obesity on fibroblast growth factor 23 (FGF-23), which is important in bone mineralization, have not yet been clarified. Our aim was to investigate the association between FGF-23 concentration and obesity-associated dysmetabolism.
Methods
Subjects comprised 46 obese children and adolescents. The same number of age-matched, healthy controls were recruited. Markers of bone mineralization and glucose metabolism were measured. Thyroid function and insulin resistance were investigated in both groups. In obese subjects; an oral glucose tolerance test (OGTT) was performed and hemoglobin A1c and lipid fractions were measured. Bone mineral density and hepatic steatosis were investigated.
Results
Serum FGF-23, α-klotho and 1,25(OH)2D3 concentrations were significantly lower while fasting insulin, fasting glucose, C-peptide and alkaline phosphatase (ALP) concentrations and homeostasis model assessment of insulin resistance (HOMA-IR) were significantly higher in the obese group compared to controls. A significant negative correlation was observed between free tri-iodothyronine (fT3) and both FGF-23 and α-klotho in the obese group. Significant negative correlation was found between FGF-23 and C-peptide and a positive correlation was found between FGF-23 and high density lipoprotein-cholesterol (HDL-c) in the obese subjects with impaired glucose tolerance (IGT). Significant negative correlations were found between FGF-23 and both fasting insulin levels and C-peptide levels in the obese subjects with hepatic steatosis.
Conclusions
In our study, insulin resistance-associated hyperinsulinism and/or lower 1,25(OH)2D3 levels, both present in obese children and adolescents, may lead to decreased serum FGF-23 concentrations in obese subjects.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: Department of Scientific Research, Inonu University, Grant Number: 2013/95.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: None declared.
References
1. Ozbek M, Topaloğlu A. Obesity in childhood. Turk Clin J Pediatr 2007;3:47–50.Search in Google Scholar
2. Cimen M, Cimen O. Obesity and vitamin D. Mersin U J Health Sci 2016;9:102–12.Search in Google Scholar
3. Wesseling Perry K. Abnormalities of calcium, phosphorous, FGF23, vitamin D, and PTH metabolism and assessment of parathyroid hormone levels. In: Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu AS, editors. Brenner & Rector’s the kidney, 10 ed. Philadelphia, PA, USA: Elsevier, 2016:1215–9.Search in Google Scholar
4. Bringhurst F, Richard DM, Kronenberg Henry M. Actions of FGF23. Williams Textbook of Endocrinology, 13th ed. Philadelphia, USA: Elsevier, 2016:1273–5.Search in Google Scholar
5. Bär L, Feger M, Fajol A, Klotz L-O, Zeng S, et al. Insulin suppresses the production of fibroblast growth factor 23 (FGF23). Proc Natl Acad Sci USA 2018;115:5804–9.10.1073/pnas.1800160115Search in Google Scholar PubMed PubMed Central
6. Ali FN, Falkner B, Gidding SS, Price HE, Keith SW, et al. Fibroblast growth factor-23 in obese, normotensive adolescents is associated with adverse cardiac structure. J Pediatr 2014;165:738–43.10.1016/j.jpeds.2014.06.027Search in Google Scholar PubMed PubMed Central
7. Hu X, Ma X, Luo Y, Xu Y, Xiong Q, et al. Associations of serum fibroblast growth factor 23 levels with obesity and visceral fat accumulation. Clin Nutr 2018;37:223–8.10.1016/j.clnu.2016.12.010Search in Google Scholar PubMed
8. Holecki M, Chudek J, Więcek A, Titz-Bober M, Duława J. The serum level of fibroblast growth factor-23 and calcium-phosphate homeostasis in obese perimenopausal women. Int J Endocrinol 2011;2011:707126.10.1155/2011/707126Search in Google Scholar PubMed PubMed Central
9. Holecki M, Chudek J, Owczarek A, Olszanecka-Glinianowicz M, Bożentowicz-Wikarek M, et al. Inflammation but not obesity or insulin resistance is associated with increased plasma fibroblast growth factor 23 concentration in the elderly. Clin Endocrinol 2015;82:900–9.10.1111/cen.12759Search in Google Scholar PubMed
10. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001;60:2079–86.10.1046/j.1523-1755.2001.00064.xSearch in Google Scholar PubMed
11. Zhu D, Mackenzie NC, Millan JL, Farquharson C, MacRae VE. A protective role for FGF-23 in local defence against disrupted arterial wall integrity? Mol Cell Endocrinol 2013;372:1–11.10.1016/j.mce.2013.03.008Search in Google Scholar PubMed PubMed Central
12. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006;444:770–4.10.1038/nature05315Search in Google Scholar PubMed
13. Kuro-o M. Klotho and the aging process. Korean J Intern Med 2011;26:113–22.10.3904/kjim.2011.26.2.113Search in Google Scholar PubMed PubMed Central
14. Neyzi O, Gunoz H, Furman A, Bundak R, Gokcay G, et al. Weight, height, head circumference and body mass index references for Turkish children. Turkish J Paediatr Child H 2008;51:1–14.10.4274/jcrpe.2183Search in Google Scholar PubMed PubMed Central
15. Arslan M, Atmaca A, Ayvaz G, Baskal N, Beyhan Z, et al. Metabolic syndrome guideline. The Society of Endocrinology and Metobolism of Turkey, Ankara, Turkey, 2009:9.Search in Google Scholar
16. Tarım O. Thyroid hormones and growth in health and disease. J Clin Res Pediatr Endocrinol 2011;3:51.10.4274/jcrpe.v3i2.11Search in Google Scholar PubMed PubMed Central
17. Orbak PD. Diagnostic tests in children. Yakınci C, editor. Istanbul, Turkey: Nobel Bookstore, 2011.Search in Google Scholar
18. Atabek ME, Pirgon O, Kurtoglu S. Prevalence of metabolic syndrome in obese Turkish children and adolescents. Diabetes Res Clin Pract 2006;72:315–21.10.1016/j.diabres.2005.10.021Search in Google Scholar PubMed
19. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. J Pediatr 2005;115:e500–3.10.1542/peds.2004-1921Search in Google Scholar PubMed
20. Ulu MS, Yüksel S. Insulin resistance [İnsülin Direnci]. J Kocatepe Med 2015;16:238–43.Search in Google Scholar
21. Ellis KJ, Shypailo RJ, Hardin DS, Perez MD, Motil KJ, et al. Z score prediction model for assessment of bone mineral content in pediatric diseases. J Bone Miner Res 2001;16:1658–64.10.1359/jbmr.2001.16.9.1658Search in Google Scholar PubMed
22. ISCD Guidelines, The International Society for Clinical Densitometry 2013 Official Positions P. (https://www.iscd.org/official-positions/2013-iscd-official-positions-pediatric/).2013:17–20.Search in Google Scholar
23. Zaheer S, de Boer IH, Allison M, Brown JM, Psaty BM, et al. Fibroblast growth factor 23, mineral metabolism, and adiposity in normal kidney function. J Clin Endocrinol Metab 2017;102:1387–95.10.1210/jc.2016-3563Search in Google Scholar PubMed PubMed Central
24. Mirza MA, Alsiö J, Hammarstedt A, Erben RG, Michaëlsson K, et al. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol 2011;31:219–27.10.1161/ATVBAHA.110.214619Search in Google Scholar PubMed
25. Gutiérrez OM, Wolf M, Taylor EN. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol 2011;6:2871–8.10.2215/CJN.02740311Search in Google Scholar PubMed PubMed Central
26. Hanks LJ, Casazza K, Judd SE, Jenny NS, Gutiérrez OM. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS One 2015;10:e0122885.10.1371/journal.pone.0122885Search in Google Scholar PubMed PubMed Central
27. Haluzikova D, Lacinova Z, Kavalkova P, Drapalova J, Křížová J, et al. Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects. Obesity 2013;21:1335–42.10.1002/oby.20208Search in Google Scholar PubMed
28. Gómez-Ambrosi J, Gallego-Escuredo JM, Catalán V, RodríguezA, Domingo P, et al. FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet-or surgically-induced weight loss. Clin Nutr 2017;36:861–8.10.1016/j.clnu.2016.04.027Search in Google Scholar PubMed
29. Wojcik M, Dolezal-Oltarzewska K, Janus D, Drozdz D, Sztefko K, et al. FGF23 contributes to insulin sensitivity in obese adolescents–preliminary results. Clin Endocrinol 2012;77:537–40.10.1111/j.1365-2265.2011.04299.xSearch in Google Scholar PubMed
30. Wojcik M, Janus D, Dolezal-Oltarzewska K, Drozdz D, Sztefko K, et al. The association of FGF23 levels in obese adolescents with insulin sensitivity. J Pediatr Endocrinol Metab 2012;25:687–90.10.1515/jpem-2012-0064Search in Google Scholar PubMed
31. Xu Y, Sun Z. Molecular basis of Klotho: from gene to function in aging. Endocr Rev 2015;36:174–93.10.1210/er.2013-1079Search in Google Scholar PubMed PubMed Central
32. Arking DE, Becker DM, Yanek LR, Fallin D, Judge DP, et al. KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet 2003;72: 1154–61.10.1086/375035Search in Google Scholar PubMed PubMed Central
33. Arking DE, Atzmon G, Arking A, Barzilai N, Dietz HC. Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity. Circ Res 2005;96:412–8.10.1161/01.RES.0000157171.04054.30Search in Google Scholar PubMed
34. Taylor EN, Rimm EB, Stampfer MJ, Curhan GC. Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J 2011;161:956–62.10.1016/j.ahj.2011.02.012Search in Google Scholar PubMed PubMed Central
35. Wojcik M, Janus D, Kalicka-Kasperczyk A, Sztefko K, Starzyk JB. The potential impact of the hypovitaminosis D on metabolic complications in obese adolescents – preliminary results. Ann Agric Environ Med 2017;24:636–9.10.5604/12321966.1230676Search in Google Scholar PubMed
36. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. Clin J Am Soc Nephrol 2006;17:1305–15.10.1681/ASN.2005111185Search in Google Scholar PubMed
37. Marsell R, Mirza M, Mallmin H, Karlsson M, Mellström D, et al. Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. Osteoporos Int 2009;20:1167–73.10.1007/s00198-008-0780-2Search in Google Scholar PubMed
38. Yamashita H, Yamazaki Y, Hasegawa H, Yamashita T, FukumotoS, et al. Fibroblast growth factor-23 in patients with Graves’ disease before and after antithyroid therapy: its important role in serum phosphate regulation. J Clin Endocrinol Metab 2005;90:4211–5.10.1210/jc.2004-2498Search in Google Scholar PubMed
39. Park SE, Cho M, Kim SH, Rhee Y, Kang ES, et al. The adaptation and relationship of FGF-23 to changes in mineral metabolism in Graves’ disease. J Clin Endocrinol 2007;66:854–8.10.1111/j.1365-2265.2007.02824.xSearch in Google Scholar PubMed
40. Meuwese CL, Olauson H, Qureshi AR, Ripsweden J, Barany P, et al. Associations between thyroid hormones, calcification inhibitor levels and vascular calcification in end-stage renal disease. PLoS One 2015;10:e0132353.10.1371/journal.pone.0132353Search in Google Scholar PubMed PubMed Central
41. Afsar B, Yilmaz MI, Siriopol D, Unal HU, Saglam M, et al. Thyroid function and cardiovascular events in chronic kidney disease patients. J Nephrol 2016:1–8.10.1007/s40620-016-0300-ySearch in Google Scholar PubMed
42. Stevens DA, Harvey CB, Scott AJ, O’Shea PJ, Barnard JC, et al. Thyroid hormone activates fibroblast growth factor receptor-1 in bone. Mol Endocrinol 2003;17:1751–66.10.1210/me.2003-0137Search in Google Scholar PubMed
43. Kim H-Y, Mohan S. Role and mechanisms of actions of thyroid hormone on the skeletal development. Bone Res 2013;1:146.10.4248/BR201302004Search in Google Scholar PubMed PubMed Central
©2019 Walter de Gruyter GmbH, Berlin/Boston
